The start of Phase I trials for MTX102, a first-in-man diabetes immunotherapy using Midatech’s proprietary gold nanoparticle technology, is encouraging. The programme aims to reduce the immune response that causes destruction of insulin producing cells in the pancreas in Type 1 diabetes patients, which represents a potential novel treatment paradigm. We look forward to results in 2017 with anticipation.